Triple-negative breast cancers do not express the HER2 protein nor contain estrogen or progesterone receptors. They can be challenging to treat. Doctors are therefore seeking more effective therapies for this disease.
Scientists at Memorial Sloan-Kettering Cancer Center have found a subset of triple-negative breast cancers that act like estrogen-sensitive breast cancers and contain a protein called the androgen receptor. Studies have shown that blocking hormones called androgens slows the growth of breast cancer cells that lack estrogen and progesterone receptors but contain the androgen receptor.
Researchers believe that blocking the androgen receptor may slow or stop tumor growth in patients with breast cancer. The purpose of this study is to evaluate the safety and effectiveness of the drug enzalutamide in patients with advanced triple-negative breast cancer that contains the androgen receptor. Enzalutamide blocks testosterone from binding to the androgen receptor. It is approved for the treatment of men with advanced prostate cancer.
Enzalutamide is a pill that is taken orally (by mouth).